Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NCI9673
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
- NCT02314169 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Standard
We haven't built an HCP commentary report on NCI9673 (nivolumab; nivolumab plus ipilimumab in refractory metastatic anal canal squamous cell carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCI9673 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 12 | |
| YouTube | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Anal Canal Squamous Cell Carcinoma; Metastatic Anal Canal Carcinoma; Stage IV Anal Cancer AJCC v8
- Interventions
- Biospecimen Collection; Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab
- Arms
- Part A (nivolumab) · Experimental
- Part B Arm I (nivolumab) · Experimental
- Part B Arm II (nivolumab, ipilimumab) · Experimental
- Enrollment
- 143
- Primary outcomes
- Overall Response Rate: Number of Participants With Response (Part A)
- Progression-free Survival (PFS) (Part B)
- Sponsor
- National Cancer Institute (NCI)
- Start
- May 13, 2015
- Primary completion
- Feb 15, 2025
- Results posted
- Yes
- Registry record
- NCT02314169 · updated Sep 22, 2026
Publications
linked from the registry- Morris VK, Ciombor KK, Xiao L, Ochieng JK, Marmonti E, Polite B, Weinberg BA, Krauss JC, Hays J, Mukherjee S, Aranha O, Iqbal S, Shields T, Benson AB, Kazmi S, Lieu C, Hochster H, Whisenant J, Haymaker C, Eng C. NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal. J Clin Oncol. 2026 Feb 20;44(6):497-507. doi: 10.1200/JCO-25-00929. Epub 2026 Jan 7. PubMed 41499716
- Morris VK, Salem ME, Nimeiri H, Iqbal S, Singh P, Ciombor K, Polite B, Deming D, Chan E, Wade JL, Xiao L, Bekaii-Saab T, Vence L, Blando J, Mahvash A, Foo WC, Ohaji C, Pasia M, Bland G, Ohinata A, Rogers J, Mehdizadeh A, Banks K, Lanman R, Wolff RA, Streicher H, Allison J, Sharma P, Eng C. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017 Apr;18(4):446-453. doi: 10.1016/S1470-2045(17)30104-3. Epub 2017 Feb 18. PubMed 28223062